Johnson, J.R., Sannes, M.R., Croy, C., Johnson, B., Clabots, C., Kustowski, M.A., Bender, J., Smith, K.E., Winokur, P.L. and Belongia, E.A. (2007) Antimicrobial drug-resistant Esherichia coli from human and poultry products Minnesota and Wisconsin. Emerging Infectious Diseases, 13, 1576-1585. doi:10.3201/eid1306.061576

has been cited by the following article:

• TITLE: Effective treatment of resistant Escherichia coli infection, with sulphadimidine stabilized in a synthetic Aluminium-Magnesium Silicate

  AUTHORS: Maduike C. O. Ezeibe, Uchenna M. Chima, Augustine A. Ngene, Obianuju N. Okoroafor, Idika I. Kalu, Mfon E. Esen

  KEYWORDS: Resistant Pathogens; Escherichia coli; Sulphadimidine; Aluminium-Magnesium Silicate;Nanoparticles

  JOURNAL NAME: Health, Vol.4 No.12, December 12, 2012

  ABSTRACT: To investigate if Aluminium-Magnesium Silicate (AMS) could make drugs regain effects against resistant pathogens, its effect was tested on sulphadimidine against sulphadimidine-resistant Escherichia coli. Two groups of chicks infected with sulphadimidine-resistant E. coli were treated at sulphadimidine dose rate of 1 g/litre of drinking water, with sulphadimidine and with an AMS-sulphadimidine drug formulation, respectively. Two other groups were similarly treated at sulphadimidine dose rate of 0.75 g/litre, while the fifth group served as control. Mean titres of the bacterium in bile of the chicks were compared. Titres, 119,200 ± 55,800 CFU/mL of the group treated with sulphadimidine at rate of 1 g/ litre and 14,800 ± 1700 CFU/mL of the group treated at rate of 0.75 g/litre, did not vary from 33,200 ± 5200 CFU/mL of the control (P > 0.05) but 295,200 ± 106,400 CFU/ml of the group treated at rate of 1 g/litre, with the AMS-sulpha- dimidine drug was significantly (P